Silencing MR-1 attenuates inflammatory damage in mice heart induced by AngII

Biochemical and Biophysical Research Communications

Volumn 391, Issue 3, 2010, Pages 1573-1578

  Dai, Wenjian ^a,b   chen, Haiyang ^b   Jiang, Jiandong ^a   Kong, Weijia ^a   Wang, Yiguang ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b Hunan Environment Biological Polytechnic   (China)

Author keywords

Angiotensin II; AP 1; MR 1; Myocardium inflammation; NF B

Indexed keywords

ANGIOTENSIN II; CD31 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MYOFIBRILLOGENESIS REGULATOR 1 PROTEIN; PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDITIS; CELL INFILTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; GENE; GENE SILENCING; HEART; HEART MUSCLE; INFLAMMATORY CELL; INJECTION; MALE; MOUSE; MR 1 GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANGIOTENSIN II; ANIMALS; GENE KNOCKDOWN TECHNIQUES; MICE; MUSCLE PROTEINS; MYOCARDITIS; MYOCARDIUM; NF-KAPPA B; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR AP-1;

MUS;

EID: 73949147868     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.12.130     Document Type: Article

References (35)

1. Li T.-b., Liu X., Feng S., Hu Y., Yang W., Han Y., Wang Y., and Gong L. Characterization of MR-1, a novel myofibrillogenesis regulator in human muscle. Acta Biochem. Biophys. Sin. 36 (2004) 405-411
2. Li H.L., She Z.G., Li T.B., Wang A.B., Yang Q., Wei Y.S., Wang Y.G., and Liu D.P. Overexpression of myofibrillogenesis regulator-1 aggravates cardiac hypertrophy induced by angiotensin II in mice. Hypertension 49 (2007) 1399-1408
3. Liu X., Li T., Sun S., Xu F., and Wang Y. Role of myofibrillogenesis regulator-1 in myocardial hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H279-H285
4. Kim S., Ohta K., Hamaguchi A., Yukimura T., Miura K., and Iwao H. Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension 25 (1995) 1252-1259
5. Susic D., Nunez E., Frohlich E.D., and Prakash O. Angiotensin II increases left ventricular mass without affecting myosin isoform mRNAs. Hypertension 28 (1996) 265-268
6. Kiarash A., Pagano P.J., Tayeh M., Rhaleb N.E., and Carretero O.A. Upregulated expression of rat heart intercellular adhesion molecule-1 in angiotensin II- but not phenylephrine-induced hypertension. Hypertension 37 (2001) 58-65
7. Weber K.T., and Brilla C.G. Pathological hypertrophy and cardiac interstitium Fibrosis and renin-angiotensin-aldosterone system. Circulation 83 (1991) 1849-1865
8. Muller D.N., Dechend R., Mervaala E.M., Park J.K., Schmidt F., Fiebeler A., Theuer J., Breu V., Ganten D., Haller H., and Luft F.C. NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 35 (2000) 193-201
9. Muller D.N., Dechend R., Mervaala E.M.A., Park J.-K., Schmidt F., Fiebeler A., Theuer J., Breu V., Ganten D., Haller H., and Luft F.C. NF-κB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 35 (2000) 193-201
10. Theuer J., Dechend R., Muller D.N., Park J.K., Fiebeler A., Barta P., Ganten D., Haller H., Dietz R., and Luft F.C. Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats. BMC Cardiovasc. Disord. 2 (2002) 3
11. Das U.N. Angiotensin-II behaves as an endogenous pro-inflammatory molecule. J. Assoc. Physicians India 53 (2005) 472-476
12. Lu L., Chen S.S., Zhang J.Q., Ramires F.J., and Sun Y. Activation of nuclear factor-kappaB and its proinflammatory mediator cascade in the infarcted rat heart. Biochem. Biophys. Res. Commun. 321 (2004) 879-885
13. Diep Q.N., Benkirane K., Amiri F., Cohn J.S., Endemann D., and Schiffrin E.L. PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J. Mol. Cell Cardiol. 36 (2004) 295-304
14. Duxbury M.S., Matros E., Ito H., Zinner M.J., Ashley S.W., and Whang E.E. Systemic siRNA-mediated gene silencing: a new approach to targeted therapy of cancer. Ann. Surg. 240 (2004) 667-674
15. Friddle C.J., Koga T., Rubin E.M., and Bristow J. Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy. Proc. Natl. Acad. Sci. USA 97 (2000) 6745-6750
16. Collins A.R., Schnee J., Wang W., Kim S., Fishbein M.C., Bruemmer D., Law R.E., Nicholas S., Ross R.S., and Hsueh W.A. Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart. J. Am. Coll. Cardiol. 43 (2004) 1698-1705
17. Clemente C.F.M.Z., Tornatore T.F., Theizen T.H., Deckmann A.C., Pereira T.C., Lopes-Cendes I., Souza J.R.M., and Franchini K.G. Targeting focal adhesion kinase with small interfering RNA prevents and reverses load-induced cardiac hypertrophy in mice. Circ. Res. 101 (2007) 1339-1348
18. Niu J., Azfer A., Deucher M.F., Goldschmidt-Clermont P.J., and Kolattukudy P.E. Targeted cardiac expression of soluble Fas prevents the development of heart failure in mice with cardiac-specific expression of MCP-1. J. Mol. Cell Cardiol. 40 (2006) 810-820
19. Sorensen D.R., Leirdal M., and Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J. Mol. Biol. 327 (2003) 761-766
20. Modlinger P., Chabrashvili T., Gill P.S., Mendonca M., Harrison D.G., Griendling K.K., Li M., Raggio J., Wellstein A., Chen Y., Welch W.J., and Wilcox C.S. RNA silencing in vivo reveals role of p22phox in rat angiotensin slow pressor response. Hypertension 47 (2006) 238-244
21. Dykxhoorn D.M., and Lieberman J. Knocking down disease with siRNAs. Cell 126 (2006) 231-235
22. Sørensen D.R., Leirdal M., and Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J. Mol. Biol. 327 (2003) 761-766
23. Das U.N. Is angiotensin II an endogenouspro-inflammatory molecule?. Med. Sci. Monit. 11 (2005) 155-162
24. Tham D.M., and Martin-McNulty B. Wang YX et al. Angiotensin II is associated with activation of NF-κB mediated genes and downregulation of PPARs, Physiol Genom. 11 (2002) 21-31
25. Valen G., Yan Z.Q., and Hansson G.K. Nuclear factor-κB and the heart. J. Am. Coll. Cardiol. 38 (2001) 307-314
26. Alexander R.W. Hypertension and the pathogenesis of atherosclerosis: oxidative stress and the mediation of arterial inflammatory response, a new perspective. Hypertension 25 (1995) 155-161
27. Griendling K.K., and FitzGerald G.A. Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation 108 (2003) 2034-2040
28. Touyz R.M. Role of angiotensin II in regulating vascular structural and functional changes in hypertension. Curr. Hypertens. Rep. 5 (2003) 155-164
29. Schiffrin E.L. Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am. J. Physiol. Heart Circ. Physiol. 288 (2005) H1037-H1043
30. Ren K., Jin H., Bian C., He H., Liu X., Zhang S., Wang Y., and Shao R.G. MR-1 modulates proliferation and migration of human hepatoma HepG2 cells through myosin light chains-2 (MLC2)/focal adhesion kinase (FAK)/Akt signaling pathway. J. Biol. Chem. 283 (2008) 35598-35605
31. Funakoshi-Tago M., Sonoda Y., Tanaka S., Hashimoto K., Tago K., Tominaga S., and Kasahara T. Tumor necrosis factor-induced nuclear factor kappaB activation is impaired in focal adhesion kinase-deficient fibroblasts. J. Biol. Chem. 278 (2003) 29359-29365
32. Huang D., Khoe M., Befekadu M., Chung S., Takata Y., Ilic D., and Bryer-Ash M. Focal adhesion kinase mediates cell survival via NF-kappaB and ERK signaling pathways. Am. J. Physiol. Cell Physiol. 292 (2007) C1339-C1352
33. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell Biol. 10 (1998) 262-267
34. McBride K., and Nemer M. The C-terminal domain of c-Fos is required for activation of an AP-1 site required for activation of an AP-1 site specific for Jun-Fos herterodimers. Mol. Cell. Biol. 18 (1998) 5073-5081
35. Chen Y., and Currie R.W. Heat shock treatment suppresses angiotensin II-induced SP-1 and AP-1 and stimulates Oct-1 DNA-binding activity in heart. Inflamm. Res. 54 (2005) 338-343